This segment focuses on the research, development, and clinical evaluation of efruxifermin (EFX), a fibroblast growth factor 21 (FGF21) analog, for the treatment of nonalcoholic steatohepatitis (NASH). Research and development activities include preclinical studies, Phase 2 and Phase 3 clinical trials (SYNCHRONY program), and analysis of clinical data to assess efficacy and safety. The technology platform centers around EFX's mechanism of action, which targets metabolic pathways to reduce liver fat, inflammation, and fibrosis. The primary therapeutic area is NASH, a chronic liver disease with significant unmet medical needs. The goal is to improve liver health and prevent disease progression, potentially impacting millions of patients. Akero's market positioning is as a clinical-stage company with a promising lead candidate. Future opportunities include expanding the use of EFX and potentially developing combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships and collaborations may be sought to support clinical development and commercialization.